Literature DB >> 31253940

The role of telomeres and telomerase in cirrhosis and liver cancer.

Jean-Charles Nault1,2,3, Massih Ningarhari4, Sandra Rebouissou4, Jessica Zucman-Rossi5,6.   

Abstract

Telomerase is a key enzyme for cell survival that prevents telomere shortening and the subsequent cellular senescence that is observed after many rounds of cell division. In contrast, inactivation of telomerase is observed in most cells of the adult liver. Absence of telomerase activity and shortening of telomeres has been implicated in hepatocyte senescence and the development of cirrhosis, a chronic liver disease that can lead to hepatocellular carcinoma (HCC) development. During hepatocarcinogenesis, telomerase reactivation is required to enable the uncontrolled cell proliferation that leads to malignant transformation and HCC development. Part of the telomerase complex, telomerase reverse transcriptase, is encoded by TERT, and several mechanisms of telomerase reactivation have been described in HCC that include somatic TERT promoter mutations, TERT amplification, TERT translocation and viral insertion into the TERT gene. An understanding of the role of telomeres and telomerase in HCC development is important to develop future targeted therapies and improve survival of this disease. In this Review, the roles of telomeres and telomerase in liver carcinogenesis are discussed, in addition to their potential translation to clinical practice as biomarkers and therapeutic targets.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31253940     DOI: 10.1038/s41575-019-0165-3

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN: 1759-5045            Impact factor:   46.802


  174 in total

Review 1.  Molecular profiling of liver tumors: classification and clinical translation for decision making.

Authors:  Roser Pinyol; Jean Charles Nault; Iris M Quetglas; Jessica Zucman-Rossi; Josep M Llovet
Journal:  Semin Liver Dis       Date:  2014-11-04       Impact factor: 6.115

Review 2.  Hepatocellular carcinoma.

Authors:  Hashem B El-Serag
Journal:  N Engl J Med       Date:  2011-09-22       Impact factor: 91.245

3.  Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial.

Authors:  Jordi Bruix; Jean-Luc Raoul; Morris Sherman; Vincenzo Mazzaferro; Luigi Bolondi; Antonio Craxi; Peter R Galle; Armando Santoro; Michel Beaugrand; Angelo Sangiovanni; Camillo Porta; Guido Gerken; Jorge A Marrero; Andrea Nadel; Michael Shan; Marius Moscovici; Dimitris Voliotis; Josep M Llovet
Journal:  J Hepatol       Date:  2012-06-19       Impact factor: 25.083

Review 4.  Pathogenesis of hepatocellular carcinoma according to aetiology.

Authors:  Jean-Charles Nault
Journal:  Best Pract Res Clin Gastroenterol       Date:  2014-08-23       Impact factor: 3.043

5.  Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.

Authors:  Masatoshi Kudo; Richard S Finn; Shukui Qin; Kwang-Hyub Han; Kenji Ikeda; Fabio Piscaglia; Ari Baron; Joong-Won Park; Guohong Han; Jacek Jassem; Jean Frederic Blanc; Arndt Vogel; Dmitry Komov; T R Jeffry Evans; Carlos Lopez; Corina Dutcus; Matthew Guo; Kenichi Saito; Silvija Kraljevic; Toshiyuki Tamai; Min Ren; Ann-Lii Cheng
Journal:  Lancet       Date:  2018-03-24       Impact factor: 79.321

Review 6.  Genetic Landscape and Biomarkers of Hepatocellular Carcinoma.

Authors:  Jessica Zucman-Rossi; Augusto Villanueva; Jean-Charles Nault; Josep M Llovet
Journal:  Gastroenterology       Date:  2015-06-20       Impact factor: 22.682

Review 7.  Hepatocellular carcinoma.

Authors:  Alejandro Forner; Josep M Llovet; Jordi Bruix
Journal:  Lancet       Date:  2012-02-20       Impact factor: 79.321

Review 8.  Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design.

Authors:  Josep M Llovet; Virginia Hernandez-Gea
Journal:  Clin Cancer Res       Date:  2014-03-03       Impact factor: 12.531

9.  Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.

Authors:  Jordi Bruix; Shukui Qin; Philippe Merle; Alessandro Granito; Yi-Hsiang Huang; György Bodoky; Marc Pracht; Osamu Yokosuka; Olivier Rosmorduc; Valeriy Breder; René Gerolami; Gianluca Masi; Paul J Ross; Tianqiang Song; Jean-Pierre Bronowicki; Isabelle Ollivier-Hourmand; Masatoshi Kudo; Ann-Lii Cheng; Josep M Llovet; Richard S Finn; Marie-Aude LeBerre; Annette Baumhauer; Gerold Meinhardt; Guohong Han
Journal:  Lancet       Date:  2016-12-06       Impact factor: 79.321

10.  Sorafenib in advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245

View more
  43 in total

Review 1.  Hepatocellular carcinoma.

Authors:  Josep M Llovet; Robin Kate Kelley; Augusto Villanueva; Amit G Singal; Eli Pikarsky; Sasan Roayaie; Riccardo Lencioni; Kazuhiko Koike; Jessica Zucman-Rossi; Richard S Finn
Journal:  Nat Rev Dis Primers       Date:  2021-01-21       Impact factor: 52.329

Review 2.  Data Centric Molecular Analysis and Evaluation of Hepatocellular Carcinoma Therapeutics Using Machine Intelligence-Based Tools.

Authors:  Rengul Cetin-Atalay; Deniz Cansen Kahraman; Esra Nalbat; Ahmet Sureyya Rifaioglu; Ahmet Atakan; Ataberk Donmez; Heval Atas; M Volkan Atalay; Aybar C Acar; Tunca Doğan
Journal:  J Gastrointest Cancer       Date:  2021-12-15

Review 3.  Current Perspectives on the Immunosuppressive Niche and Role of Fibrosis in Hepatocellular Carcinoma and the Development of Antitumor Immunity.

Authors:  Tomoko Aoki; Naoshi Nishida; Masatoshi Kudo
Journal:  J Histochem Cytochem       Date:  2021-11-09       Impact factor: 2.479

Review 4.  Benign liver tumours: understanding molecular physiology to adapt clinical management.

Authors:  Jean-Charles Nault; Valérie Paradis; Maxime Ronot; Jessica Zucman-Rossi
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2022-07-14       Impact factor: 73.082

Review 5.  Genetics of human telomere biology disorders.

Authors:  Patrick Revy; Caroline Kannengiesser; Alison A Bertuch
Journal:  Nat Rev Genet       Date:  2022-09-23       Impact factor: 59.581

Review 6.  Pituitary Tumor-Transforming Gene 1/Delta like Non-Canonical Notch Ligand 1 Signaling in Chronic Liver Diseases.

Authors:  Meritxell Perramón; Wladimiro Jiménez
Journal:  Int J Mol Sci       Date:  2022-06-21       Impact factor: 6.208

Review 7.  Tumour evolution in hepatocellular carcinoma.

Authors:  Amanda J Craig; Johann von Felden; Teresa Garcia-Lezana; Samantha Sarcognato; Augusto Villanueva
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-12-02       Impact factor: 46.802

8.  Mutations in circulating tumor DNA predict primary resistance to systemic therapies in advanced hepatocellular carcinoma.

Authors:  Johann von Felden; Amanda J Craig; Teresa Garcia-Lezana; Ismail Labgaa; Philipp K Haber; Delia D'Avola; Amon Asgharpour; Douglas Dieterich; Antoinette Bonaccorso; Miguel Torres-Martin; Daniela Sia; Max W Sung; Parissa Tabrizian; Myron Schwartz; Josep M Llovet; Augusto Villanueva
Journal:  Oncogene       Date:  2020-10-23       Impact factor: 9.867

Review 9.  HBV Integration Induces Complex Interactions between Host and Viral Genomic Functions at the Insertion Site.

Authors:  Dake Zhang; Ke Zhang; Urlike Protzer; Changqing Zeng
Journal:  J Clin Transl Hepatol       Date:  2021-04-25

Review 10.  Multiple Roles for Hepatitis B and C Viruses and the Host in the Development of Hepatocellular Carcinoma.

Authors:  Kirk J Wangensteen; Kyong-Mi Chang
Journal:  Hepatology       Date:  2020-11-07       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.